GLTO
Galecto, Inc.30.00
-1.60-5.06%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
47.78MP/E (TTM)
-Basic EPS (TTM)
-12.11Dividend Yield
0%Recent Filings
10-Q
Q3 FY2025 results
Galecto narrowed Q3 operating losses to $3.2M from $3.8M y/y, trimming total expenses 18% via lower G&A while R&D ticked up 30% on GB3226 chemistry work. Nine-month net loss improved to $9.1M from $14.7M y/y, reflecting post-restructuring discipline; EPS reconciles consistently at $6.88 loss on 1.32M diluted shares. Cash burned $7.3M in operating activities ytd, leaving $7.6M at quarter-end—enough for GB3226 preclinical into 2026 per MD&A, yet going concern doubts persist without new funding. Acquired GB3226 (ex-BRM-1420) in Oct 2024 via stock/preferred issuance, no goodwill noted. Cash runway tightens fast.
10-Q
Q2 FY2025 results
Galecto narrowed Q2 losses to $3.4M from $5.3M y/y, with operating expenses dropping 39% to $3.4M on lower R&D ($1.5M, -20%) and G&A ($2.0M, -30%), no repeat of prior restructuring costs. Net loss per share improved to $(2.60) from $(4.92) on 1.3M diluted shares. Cash burned $4.7M YTD to $10.2M, sufficient for GB3226 preclinical into 2026 per MD&A; no debt, no capex so FCF not disclosed in the 10-Q. Acquired GB3226 (AML asset) in Oct 2024 via Bridge Purchase Agreement for 62,594 common shares and 161 Series A preferred shares (159 outstanding). Cash runway tightens. Nasdaq listing hangs in balance.
8-K
Stockholders approve directors, conversion
Galecto stockholders approved electing Carl Goldfischer, M.D., and David Shapiro, M.D., as Class II directors at the June 18, 2025, annual meeting. They also greenlit issuing common shares upon conversion of Series A preferred stock issued to Bridge Medicines on October 7, 2024, and ratified EY as auditors for 2025. All proposals passed decisively. Nasdaq compliance secured.
10-Q
Q1 FY2025 results
Galecto narrowed its Q1 FY2025 operating loss to $2.6M from $5.7M y/y, slashing R&D expenses 72.5% to $0.7M and G&A 41.4% to $1.9M amid its oncology/liver disease pivot to GB3226 and GB1211. Net loss improved to $2.5M ($1.92/share) versus $5.5M ($5.05/share), matching 1.3M diluted shares. Cash burned $2.4M in operations, leaving $11.9M at March 31, 2025—enough for GB3226 preclinical into 2026, per MD&A. Cash burn slowed sharply. No debt weighs the balance sheet. Tariffs threaten supply chain costs.
10-K
FY2024 results
Galecto posted FY2024 results for the year ended December 31, 2024, marked by a strategic pivot in October 2024 acquiring global rights to GB3226 (ex-BRM-1420), a preclinical AML dual inhibitor, while dropping GB2064 and narrowing focus to oncology/liver diseases with GB1211. No revenue or quarterly financials disclosed in the 10-K; cash lasts into 2026 for GB3226 preclinical work and planned Q1 2026 FDA IND. Post-acquisition, issued retention bonuses to CEO (DKK 2.2M) and exec (US$160K) through 2025. Reverse split hit August 2024; shares outstanding 1.3M as of March 2025. Auditors flag going concern doubts. Cash burn threatens program delays.
AVTX
Avalo Therapeutics, Inc.
18.82+1.12
CBIO
Crescent Biopharma, Inc.
12.92-0.29
ELVN
Enliven Therapeutics, Inc.
16.91-0.26
ENTO
Entero Therapeutics Inc.
2.99+0.15
FBLG
FibroBiologics, Inc.
0.24-0.02
GALT
Galectin Therapeutics Inc.
6.20-0.31
GBIO
Generation Bio Co.
5.38-0.01
GLMD
Galmed Pharmaceuticals Ltd.
0.98+0.01
GLPG
Galapagos NV
31.08-0.03
GRI
GRI Bio, Inc.
0.48+0.00